HK Stock Market Move | INSILICO (03696) closing up nearly 14%, officially entering the CSI Index Series this week. Since going public, it has been included in several major index series.

INSILICO (03696) rose against the market all day, closing up 13.84% at HK$38.34 with a turnover of HK$3.38 billion. On the news front, INSILICO has been included in the CSI series index effective from June 15th (this Monday). Since its listing on the Hong Kong Stock Exchange, INSILICO has been included in several major index series before gaining recognition in the CSI series, including the Hang Seng Composite Index, Hang Seng Healthcare Index, Hang Seng Biotechnology Index, FTSE Global Small Cap Index, FTSE Global All Cap Index, FTSE Global Total Cap Index, CSI Hong Kong Stock Connect Innovative Drug Index, CSI Hong Kong Innovative Drug Index, and CSI Hong Kong Stock Connect Pharmaceuticals and Healthcare Comprehensive Index. It is worth noting that INSILICO announced the achievement of the first clinical milestone for ISM8969, developed jointly with Hengtai Biology, completing the first human dosing in a Phase I clinical study. ISM8969 is an orally bioavailable, blood-brain barrier penetrant small molecule NLRP3 inflammasome inhibitor with potential best-in-class capabilities, intended for the treatment of chronic neuroinflammation and central nervous system (CNS) diseases, including Parkinson's disease. Under the agreement, both parties hold a 50% global equity stake in the project.